Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 11:47 AM
Ignite Modification Date:
2025-12-26 @ 11:47 AM
NCT ID:
NCT00004916
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed intermediate or high grade non-Hodgkin's lymphoma
* No lymphoblastic or small cleaved lymphoma
* Progressive disease following doxorubicin based chemotherapy
* No more than 2 prior treatment regimens
* Measurable or evaluable disease NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* ECOG 0-2
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* Bilirubin no greater than 2 times upper limit of normal
Renal:
* Creatinine no greater than 2.0 mg/dL
Cardiovascular:
* No significant cardiac disease
Other:
* Not pregnant or nursing
* Fertile patients must use effective contraception
* No active or uncontrolled second malignancy
* No other medical problems that would preclude therapy
* HIV negative
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Prior stem cell transplant allowed
Chemotherapy:
* See Disease Characteristics
Endocrine therapy:
* Not specified
Radiotherapy:
* Not specified
Surgery:
* Not specified
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00004916
Study Brief:
Protocol Section:
NCT00004916